title: Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads.
abstract: BACKGROUND
  Persistent low CD4(+) cell counts are observed in 5%-27% of patients treated for human immunodeficiency virus (HIV)-1 infection despite their having prolonged undetectable plasma viral loads.
  
  
  METHODS
  To understand the possible mechanisms of this discordant immunological situation, a prospective transsectional case-control study was designed. HIV-1-infected subjects who had a plasma viral load <200 copies/mL for >1 year were considered to be case patients if their CD4(+) cell count was <250/mm(3); control patients had CD4(+) cell counts >500/mm(3) and were matched by sex, age, and nadir CD4(+) cell count to case patients. T cell proliferation after stimulation with various antigens, T cell subset counts, T cell rearrangement excision circles (TRECs), T cells undergoing apoptosis, cytokines influencing apoptosis, and cellular proviral DNA and plasma viral RNA persistence were assessed.
  
  
  RESULTS
  Compared with the 19 control patients, the 19 case patients had undistinguishable lymphoproliferative responses to candidin and cytomegalovirus, fewer naive CD4(+) cells (CD45RA(+)62L(+), 23%+/-13% vs. 47%+/-14%; P<.0001), lower thymic output (1.28 vs. 3.95 TRECs/microL of blood; P=.0015), increased cell death by apoptosis (spontaneous, 23.2%+/-8.3% vs. 11.9%+/-8.4% [P=.02]; Fas induced, 38.6%+/-13.7% vs. 16.4%+/-8.0% [P=.004]), higher levels of plasma soluble tumor necrosis factor receptor II (9.6 vs. 5.3 ng/mL; P=.0058), and undistinguishable plasma HIV-1 and cellular proviral DNA loads.
  
  
  CONCLUSIONS
  The mechanisms responsible for the low-level regeneration of CD4(+) cells involve, at least, deficiency in the regeneration of central CD4(+) cells and excessive apoptosis.
authors.affiliation: Service de Médecine Interne, Hôpital Pitié-Salpêtrière, Paris, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Benveniste
authors.forename: Antoine
authors.initials: A
authors.lastname: Flahault
authors.forename: Florence
authors.initials: F
authors.lastname: Rollot
authors.forename: Carole
authors.initials: C
authors.lastname: Elbim
authors.forename: Jérôme
authors.initials: J
authors.lastname: Estaquier
authors.forename: Béatrice
authors.initials: B
authors.lastname: Pédron
authors.forename: Xavier
authors.initials: X
authors.lastname: Duval
authors.forename: Nathalie
authors.initials: N
authors.lastname: Dereuddre-Bosquet
authors.forename: Pascal
authors.initials: P
authors.lastname: Clayette
authors.forename: Ghislaine
authors.initials: G
authors.lastname: Sterkers
authors.forename: Anne
authors.initials: A
authors.lastname: Simon
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Ameisen
authors.forename: Catherine
authors.initials: C
authors.lastname: Leport
mesh_terms: D000328:Adult; D000956:Antigens, Viral; D023241:Antiretroviral Therapy, Highly Active; D017209:Apoptosis; D015496:CD4-Positive T-Lymphocytes / Q000502:physiology*; D018414:CD8-Positive T-Lymphocytes / Q000502:physiology; D016022:Case-Control Studies; D016207:Cytokines / Q000097:blood; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D015497:HIV-1; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood; D013950:Thymus Gland / Q000166:cytology; D013997:Time Factors; D019562:Viral Load
chemical_list: D000956:Antigens, Viral; D016207:Cytokines; D012367:RNA, Viral